Exelixis Inc(EXEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 20.45 | EPS (ttm) | 3.18 | Insider Own | 3.22% | Shs Outstand | 248.9M | Perf Week | 3.88% |
| Market Cap | 16.13B | Forward P/E | 15.52 | EPS next Y | 17.77% | Insider Trans | -2.79% | Shs Float | 239.8M | Perf Month | 11.95% |
| Enterprise Value | 15.46B | PEG | 0.81 | EPS next Q | 0.89 | Inst Own | 105.81% | Short Float | 11.75% | Perf Quarter | 15.22% |
| Income | 0.86B | P/S | 6.62 | EPS this Y | 15.69% | Inst Trans | -1.1% | Short Ratio | 11.91 | Perf Half Y | 45.82% |
| Sales | 2.44B | P/B | 8.79 | EPS next 5Y | 19.22% | ROA | 33.28% | Short Interest | 28.18M | Perf YTD | 48.55% |
| Book/sh | 7.41 | P/C | 19.22 | EPS past 3/5Y | 70.35% 51.19% | ROE | 44.39% | 52W High | -0.6% ($65.50) | Perf Year | 68.16% |
| Cash/sh | 3.39 | P/FCF | 13.76 | Sales past 3/5Y | 12.93% 18.63% | ROIC | 42.82% | 52W Low | 80.86% ($36.00) | Perf 3Y | 210.2% |
| Dividend Est. | - | EV/EBITDA | 15.15 | EPS Y/Y TTM | 53.08% | Gross Margin | 96.48% | Volatility(W/M) | 1.79% 2.62% | Perf 5Y | 200.6% |
| Dividend TTM | - | EV/Sales | 6.35 | Sales Y/Y TTM | 9.23% | Oper. Margin | 40.72% | ATR (14) | 1.53 | Perf 10Y | 482.38% |
| Dividend Ex-Date | - | Quick Ratio | 3.38 | EPS Q/Q | 25.63% | Profit Margin | 35.33% | RSI (14) | 72.34 | Recom | 2.47 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.46 | Sales Q/Q | 10.63% | SMA20 | 6.75% ($60.99) | Beta | 0.47 | Target Price | $55.5 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/10/29 | SMA50 | 11.66% ($58.31) | Rel Volume | 0.71 | Prev Close | $64.53 |
| Employees | 1077 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 6.63% -1.21% | SMA200 | 29.02% ($50.47) | Avg Volume(3M) | 2.37M | Price | $65.11 |
| IPO | 2000/4/11 | Option/Short | Yes/Yes | Trades | 22186 | Volume | 1,674,898 | Change | 0.9% |
A commercial-stage biopharmaceutical company headquartered in California, USA, specializing in oncology. Its key product is Cabometyx, a targeted cancer therapy used to treat kidney cancer, and the company generates revenue while developing follow-up oncology drugs.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded less than usual. That is 71% of its average volume.
Next earnings report: October 29
2 days to go.
EXEL makes money exceptionally well
Of every $100 in sales, $40.72 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +15.7% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,045. Peers typically go for $3,449. Compared with its own 5-year average, it is 11% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +200.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 105.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #14 of 594 in the industry
Based on market cap of $16B.
FAQ
What kind of company is EXEL?
EXEL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EXEL?
The market cap of EXEL is approximately $16.1B, ranking 674 within its sector.
What is the P/E ratio of EXEL?
EXEL has a P/E ratio of approximately 20.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for EXEL?
EXEL has recorded a 52-week high of $65.50 and a low of $36.00.
